Skip to main content Back to Top
Advertisement

9/19/2019

Deferoxamine Injection

Products Affected - Description

    • Deferoxamine injection, Alvogen, 2 gram, vial, 1 count, NDC 47781-0624-07
    • Deferoxamine injection, Alvogen, 500 mg, vial, 1 count, NDC 47781-0623-07

Reason for the Shortage

    • Fresenius Kabi had deferoxamine on shortage due to increased demand.
    • Pfizer has deferoxamine on shortage due to manufacturing delays.
    • Novartis has Desferal available.
    • Alvogen did not provide a reason for the shortage. Alvogen launched deferoxamine injection in mid-2018.
    • Apo-Pharma launched deferoxamine injection in mid-2018.

Available Products

    • Desferal injection, Novartis, 500 mg, vial, 4 count, NDC 00078-0467-91
    • Deferoxamine injection, Apo-Pharma, 2 gram, vial, 4 count, NDC 52609-4504-06
    • Deferoxamine injection, Apo-Pharma, 500 mg, vial, 4 count, NDC 52609-4505-06
    • Deferoxamine injection, Fresenius Kabi, 2 gram, vial, 1 count, NDC 63323-0599-30
    • Deferoxamine injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0597-10
    • Deferoxamine injection, Pfizer, 2 gram, vial, 4 count, NDC 00409-2337-25
    • Deferoxamine injection, Pfizer, 500 mg, vial, 4 count, NDC 00409-2336-10

Estimated Resupply Dates

    • Alvogen has short-dated deferoxamine 500 mg and 2 gram vials available with an expiration date of January 2020 for the 500 mg vials and June 2020 for the 2 gram vials.

Updated

Updated September 19, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins